Company intelligence / Profile preview

Artax Biopharma

Cambridge, Massachusetts, United Statesartaxbiopharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Artax Biopharma’s lead candidate AX-158 has achieved clinical validation in a Phase 2a trial for mild to moderate plaque psoriasis. The study demonstrated statistically significant improvements in disease biomarkers and PASI scores with a well-tolerated safety profile—no infections or discontinuations were reported. The company’s approach modulates T cell activity without causing immunosuppression, potentially offering broad utility across multiple autoimmune indications. Additional trials are planned for atopic dermatitis and other autoimmune diseases.

Therapeutic areas: ImmunologyDermatologyRheumatology
Modalities: Small molecules (specifically oral small molecule Nck modulators)
Industry: Biotech

Drug pipeline

3 assets

AX-158

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Artax Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artax Biopharma.

Explore the full profile